Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

GlycoMimetics to Present at Four Investor Conferences This Month

Posted on: 07 Mar 18

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will present at four investor conferences during the month of March, including:

30 th Annual ROTH Conference
March 11 – 14, 2018, The Ritz Carlton, Dana Point, CA
CFO Brian Hahn will present on March 12 at 3:30 p.m. PT.

Cowen 38 th Annual Health Care Conference
March 11 – 14, 2018, Copley Place Marriott, Boston, MA
CEO Rachel King will present on March 14 at 9:20 a.m. ET.

BioCentury: 25 th Annual Future Leaders in the BioTech Industry
March 23, 2018, Millennium Broadway Hotel & Conference Center, New York, NY
Mrs. King will present in room 311 at 2:30 p.m. ET.

Needham & Company’s 17 th Annual HealthCare Conference
March 27 – 28, 2018, Westin Grand Central Hotel, New York, NY
Mrs. King will present on March 27 at 8:00 a.m. ET.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is currently being evaluated in a Phase 1 clinical trial for the treatment of multiple myeloma. The FDA granted GMI-1271 Breakthrough Therapy designation for the treatment of adult AML patients with relapsed/refractory disease. GlycoMimetics has also recently initiated a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at

View source version on

Business Wire

Last updated on: 07/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.